NCT02470039 - Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

insulin 338 (GIPET I)

Oral administered once daily in combination with metformin with or without DPP-4 inhibitor

DRUG

insulin glargine

Injected s.c./subcutaneously (under the skin) once daily in combination with metformin with or without DPP-4 inhibitor

DRUG

placebo

Administered once daily

Trial Locations (2)

Novo Nordisk Investigational Site, Neuss

Novo Nordisk Investigational Site, Mainz